Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2022
|
Jens Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,731
+46.82%
|
-
|
|
Jun 14
2022
|
Jens Holstein Director |
SELL
Open market or private sale
|
Direct |
8,720
-81.34%
|
$139,520
$16.27 P/Share
|
|
Jun 10
2022
|
Marc Stapley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+27.3%
|
$960,000
$16.33 P/Share
|
|
Jun 08
2022
|
Kevin K Gordon Director |
SELL
Open market or private sale
|
Direct |
15,000
-63.24%
|
$270,000
$18.5 P/Share
|
|
Jun 08
2022
|
Kevin K Gordon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+38.74%
|
$105,000
$7.39 P/Share
|
|
Jun 02
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,008
-1.64%
|
$18,144
$18.23 P/Share
|
|
Jun 02
2022
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,047
-3.9%
|
$72,846
$18.23 P/Share
|
|
Jun 02
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,042
-2.96%
|
$36,756
$18.23 P/Share
|
|
May 01
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
736
-0.85%
|
$14,720
$20.47 P/Share
|
|
Mar 04
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
23,003
-9.69%
|
$575,075
$25.7 P/Share
|
|
Mar 04
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,407
+4.96%
|
$22,035
$5.98 P/Share
|
|
Mar 03
2022
|
Bonnie H Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,667
+16.93%
|
-
|
|
Mar 03
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,412
+34.65%
|
-
|
|
Mar 03
2022
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,537
+35.26%
|
-
|
|
Mar 03
2022
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,728
+27.47%
|
-
|
|
Mar 03
2022
|
Tina Susan Nova President, CLIA U.S. |
BUY
Grant, award, or other acquisition
|
Direct |
56,546
+42.35%
|
-
|
|
Mar 02
2022
|
Tina Susan Nova President, CLIA U.S. |
SELL
Payment of exercise price or tax liability
|
Direct |
10,695
-34.35%
|
$288,765
$27.84 P/Share
|
|
Mar 02
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,337
-21.58%
|
$279,099
$27.84 P/Share
|
|
Mar 02
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,521
-6.15%
|
$122,067
$27.84 P/Share
|
|
Feb 28
2022
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,855
+50.0%
|
-
|
|
Jan 11
2022
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.26%
|
$20,000
$4.0 P/Share
|
|
Dec 17
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
5,000
-36.44%
|
$225,000
$45.0 P/Share
|
|
Dec 17
2021
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.71%
|
$60,000
$12.12 P/Share
|
|
Dec 09
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,286
+13.3%
|
$90,288
$8.86 P/Share
|
|
Dec 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
6,125
-5.81%
|
$245,000
$40.62 P/Share
|
|
Dec 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,125
+5.43%
|
$153,125
$25.62 P/Share
|
|
Dec 06
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
9,232
-5.69%
|
$332,352
$36.25 P/Share
|
|
Dec 06
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,156
+6.89%
|
$106,028
$13.1 P/Share
|
|
Dec 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.83%
|
$35,568
$39.22 P/Share
|
|
Dec 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,288
-3.54%
|
$89,232
$39.22 P/Share
|
|
Nov 01
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-0.3%
|
$7,599
$51.8 P/Share
|
|
Nov 01
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Indirect |
4,400
-58.33%
|
$72,028,000
$16370.74 P/Share
|
|
Sep 17
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
2,600
-1.18%
|
$130,000
$50.18 P/Share
|
|
Sep 10
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
1,900
-0.86%
|
$95,000
$50.03 P/Share
|
|
Sep 08
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
926
-1.82%
|
$46,300
$50.53 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
12,531
-9.96%
|
$626,550
$50.88 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,531
+6.59%
|
$200,496
$16.96 P/Share
|
|
Sep 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,288
-3.42%
|
$118,976
$52.97 P/Share
|
|
Sep 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.76%
|
$47,424
$52.97 P/Share
|
|
Aug 02
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Indirect |
4,400
-29.22%
|
$193,600
$44.06 P/Share
|
|
Jul 19
2021
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|
|
Jun 23
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
4,375
-7.78%
|
$170,625
$39.75 P/Share
|
|
Jun 23
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+7.22%
|
$105,000
$24.69 P/Share
|
|
Jun 08
2021
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
John L Bishop Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
Evan/ Fa Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+18.38%
|
-
|
|
Jun 08
2021
|
Jens Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+44.86%
|
-
|
|
Jun 08
2021
|
Kevin K Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
9,081
-5.2%
|
$308,754
$34.28 P/Share
|